- Home
- PUMP vs INBX Comparison
PUMP vs INBX Comparison
Compare PUMP & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | INBX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 999.7M |
| IPO Year | 2017 | 2024 |
Fundamental Metrics
Financial Performance| Metric | PUMP | INBX |
|---|---|---|
| Price | $17.21 | $109.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $14.14 | ★ $150.00 |
| AVG Volume (30 Days) | ★ 5.2M | 588.0K |
| Earning Date | 04-30-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,158,000.00 | $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $4.51 | $12.80 |
| 52 Week High | $18.50 | $155.29 |
Technical Indicators
Market Signals| Indicator | PUMP | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 46.87 |
| Support Level | $14.90 | $69.30 |
| Resistance Level | N/A | $153.14 |
| Average True Range (ATR) | 0.86 | 13.15 |
| MACD | -0.03 | -4.12 |
| Stochastic Oscillator | 54.69 | 11.38 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.